You are here

Xatmep, First Ready-to-Use Methotrexate Oral Solution, Wins FDA Nod

Product indicated for leukemia and arthritis in children

The FDA has cleared Xatmep (Silvergate Pharmaceuticals), the first approved methotrexate oral solution, for use in pediatric patients with acute lymphoblastic leukemia (ALL) or polyarticular juvenile idiopathic arthritis (pJIA). The product, which consists of 2.5 mg/mL of methotrexate, requires no preparation, eliminating the need for needles, crushing or splitting tablets, or compounding tablets into a liquid formulation.

Xatmep is indicated for the:

  • Management of pediatric patients with active pJIA who have had an insufficient therapeutic response to, or are intolerant of, an adequate trial of first-line therapy, including full-dose nonsteroidal anti-inflammatory drugs (NSAIDs)
  • Treatment of pediatric patients with ALL as part of a multiphase, combination chemotherapy maintenance regimen

Methotrexate inhibits dihydrofolic acid reductase, thereby interfering with DNA synthesis, repair, and cellular replication. Actively proliferating tissues, such as malignant cells, bone marrow, fetal cells, buccal and intestinal mucosa, and cells of the urinary bladder, are generally more sensitive to this effect of methotrexate. The drug’s mechanism of action in pJIA is unknown.

The labelling for Xatmep includes a boxed warning regarding the potential for severe toxic reactions, include embryo-fetal toxicity.

Sources: Silvergate Pharmaceuticals; April 26, 2016; and Xatmep Prescribing Information; April 2017.

Recent Headlines

Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Despite older, sicker patients, mortality rate fell by a third in 10 years
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs